This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Surgical Physiology, Other  • Neurology  • Cerebrovascular Disease  • Stroke  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Alden H. Harken, MD

Arch Surg. 2005;140:352.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

If you are one of those surgeons who believes that Darwin was correct, then you must also trust the constructive fortitude of an enzyme that has survived millennia of evolutionary hurdles. It must be doing something good. And the therapeutic arrogance of selectively inhibiting this enzymatic hall-of-famer should be dangerous—like challenging the pope on scripture. But, in this issue of the ARCHIVES, this is exactly what Hua et al have done.

Polyadenosine diphosphate–ribose polymerase is a DNA repair enzyme that is concentrated in cellular royalty (like heart, brain, and skeletal muscle), while PARP is essentially absent in cellular foot soldiers (like white cells). The body is not a democracy. Polyadenosine diphosphate–ribose polymerase requires energy to accomplish its repair work; so, it makes sense that we invest in the nuclear repair of terminally differentiated cells rather than squandering remorse on a bunch of granulocytes that . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Polyadenosine Diphosphate–Ribose Polymerase Inhibition Modulates Skeletal Muscle Injury Following Ischemia Reperfusion
Hong T. Hua, Hassan Albadawi, Fateh Entabi, Mark Conrad, Michael C. Stoner, Bryan T. Meriam, Ramses Sroufe, Stuart Houser, Glenn M. LaMuraglia, and Michael T. Watkins
Arch Surg. 2005;140(4):344-351.
ABSTRACT | FULL TEXT